454 related articles for article (PubMed ID: 12438270)
1. Direct evidence for a role of cyclooxygenase 2-derived prostaglandin E2 in human head and neck xenograft tumors.
Zweifel BS; Davis TW; Ornberg RL; Masferrer JL
Cancer Res; 2002 Nov; 62(22):6706-11. PubMed ID: 12438270
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of cyclooxygenase-2 by celecoxib reverses tumor-induced wasting.
Davis TW; Zweifel BS; O'Neal JM; Heuvelman DM; Abegg AL; Hendrich TO; Masferrer JL
J Pharmacol Exp Ther; 2004 Mar; 308(3):929-34. PubMed ID: 14711936
[TBL] [Abstract][Full Text] [Related]
3. Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism.
Patel MI; Subbaramaiah K; Du B; Chang M; Yang P; Newman RA; Cordon-Cardo C; Thaler HT; Dannenberg AJ
Clin Cancer Res; 2005 Mar; 11(5):1999-2007. PubMed ID: 15756026
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of cyclooxygenase-2 activity in head and neck cancer cells by genistein.
Ye F; Wu J; Dunn T; Yi J; Tong X; Zhang D
Cancer Lett; 2004 Jul; 211(1):39-46. PubMed ID: 15194215
[TBL] [Abstract][Full Text] [Related]
5. Cyclooxygenase-2 is expressed in neuroblastoma, and nonsteroidal anti-inflammatory drugs induce apoptosis and inhibit tumor growth in vivo.
Johnsen JI; Lindskog M; Ponthan F; Pettersen I; Elfman L; Orrego A; Sveinbjörnsson B; Kogner P
Cancer Res; 2004 Oct; 64(20):7210-5. PubMed ID: 15492235
[TBL] [Abstract][Full Text] [Related]
6. Nimesulide and indomethacin induce apoptosis in head and neck cancer cells.
Pelzmann M; Thurnher D; Gedlicka C; Martinek H; Knerer B
J Oral Pathol Med; 2004 Nov; 33(10):607-13. PubMed ID: 15482327
[TBL] [Abstract][Full Text] [Related]
7. Combination of cyclooxygenase-2 inhibitors and oxaliplatin increases the growth inhibition and death in human colon cancer cells.
Lin J; Hsiao PW; Chiu TH; Chao JI
Biochem Pharmacol; 2005 Sep; 70(5):658-67. PubMed ID: 16004971
[TBL] [Abstract][Full Text] [Related]
8. Cyclooxygenase-2 (COX-2)-dependent and -independent anticarcinogenic effects of celecoxib in human colon carcinoma cells.
Maier TJ; Schilling K; Schmidt R; Geisslinger G; Grösch S
Biochem Pharmacol; 2004 Apr; 67(8):1469-78. PubMed ID: 15041464
[TBL] [Abstract][Full Text] [Related]
9. Effects of the selective COX-2 inhibitors celecoxib and rofecoxib on human vascular cells.
Niederberger E; Manderscheid C; Grösch S; Schmidt H; Ehnert C; Geisslinger G
Biochem Pharmacol; 2004 Jul; 68(2):341-50. PubMed ID: 15194006
[TBL] [Abstract][Full Text] [Related]
10. Cyclooxygenase-2-selective nonsteroidal anti-inflammatory drugs inhibit hepatocyte growth factor/scatter factor-induced angiogenesis.
Sengupta S; Sellers LA; Cindrova T; Skepper J; Gherardi E; Sasisekharan R; Fan TP
Cancer Res; 2003 Dec; 63(23):8351-9. PubMed ID: 14678996
[TBL] [Abstract][Full Text] [Related]
11. Combination of a poxvirus-based vaccine with a cyclooxygenase-2 inhibitor (celecoxib) elicits antitumor immunity and long-term survival in CEA.Tg/MIN mice.
Zeytin HE; Patel AC; Rogers CJ; Canter D; Hursting SD; Schlom J; Greiner JW
Cancer Res; 2004 May; 64(10):3668-78. PubMed ID: 15150127
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of cyclooxygenase-1 and -2 expression by targeting the endothelin a receptor in human ovarian carcinoma cells.
Spinella F; Rosanò L; Di Castro V; Nicotra MR; Natali PG; Bagnato A
Clin Cancer Res; 2004 Jul; 10(14):4670-9. PubMed ID: 15269139
[TBL] [Abstract][Full Text] [Related]
13. Effects of p53 or p27 overexpression on cyclooxygenase-2 gene expression in head and neck squamous cell carcinoma cell lines.
Lee DW; Park SW; Park SY; Heo DS; Kim KH; Sung MW
Head Neck; 2004 Aug; 26(8):706-15. PubMed ID: 15287038
[TBL] [Abstract][Full Text] [Related]
14. Gene modulation by Cox-1 and Cox-2 specific inhibitors in human colorectal carcinoma cancer cells.
Bottone FG; Martinez JM; Alston-Mills B; Eling TE
Carcinogenesis; 2004 Mar; 25(3):349-57. PubMed ID: 14633654
[TBL] [Abstract][Full Text] [Related]
15. Nonsteroidal anti-inflammatory drugs increase expression of inducible COX-2 isoform of cyclooxygenase in spinal cord of rats with adjuvant induced inflammation.
Hsueh SF; Lu CY; Chao CS; Tan PH; Huang YW; Hsieh SW; Hsiao HT; Chung NC; Lin SH; Huang PL; Lyu PC; Yang LC
Brain Res Mol Brain Res; 2004 Jun; 125(1-2):113-9. PubMed ID: 15193428
[TBL] [Abstract][Full Text] [Related]
16. Expression of cyclooxygenase-2 (COX-2) in human esophageal cancer and in vitro inhibition by a specific COX-2 inhibitor, NS-398.
Yu HP; Shi LY; Lu WH; Su YH; Li YY; Xu SQ
J Gastroenterol Hepatol; 2004 Jun; 19(6):638-42. PubMed ID: 15151617
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological profile of celecoxib, a specific cyclooxygenase-2 inhibitor.
Yoshino T; Kimoto A; Kobayashi S; Noguchi M; Fukunaga M; Hayashi A; Miyata K; Sasamata M
Arzneimittelforschung; 2005; 55(7):394-402. PubMed ID: 16080279
[TBL] [Abstract][Full Text] [Related]
18. A selective cyclooxygenase-2 inhibitor, NS398, inhibits cell growth and induces cell cycle arrest in the G2/M phase in human esophageal squamous cell carcinoma cells.
Kase S; Osaki M; Honjo S; Takeda A; Adachi K; Araki K; Ito H
J Exp Clin Cancer Res; 2004 Jun; 23(2):301-7. PubMed ID: 15354416
[TBL] [Abstract][Full Text] [Related]
19. Celecoxib: a potent cyclooxygenase-2 inhibitor in cancer prevention.
Kismet K; Akay MT; Abbasoglu O; Ercan A
Cancer Detect Prev; 2004; 28(2):127-42. PubMed ID: 15068837
[TBL] [Abstract][Full Text] [Related]
20. The effects of L-748706, a selective cyclooxygenase-2 inhibitor, on N-nitrosomethylbenzylamine-induced rat esophageal tumorigenesis.
Stoner GD; Qin H; Chen T; Carlton PS; Rose ME; Aziz RM; Dixit R
Carcinogenesis; 2005 Sep; 26(9):1590-5. PubMed ID: 15878914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
